Option Care Health, Inc. (NASDAQ:OPCH) Director Purchases $969,220.00 in Stock

Option Care Health, Inc. (NASDAQ:OPCH) Director Harry M. Jansen Kraemer, Jr. bought 43,000 shares of the business’s stock in a transaction on Friday, November 8th. The stock was bought at an average price of $22.54 per share, with a total value of $969,220.00. Following the transaction, the director now owns 326,334 shares in the company, valued at approximately $7,355,568.36. This represents a 15.18 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Option Care Health Stock Performance

NASDAQ:OPCH opened at $21.93 on Friday. The firm has a market capitalization of $3.73 billion, a PE ratio of 18.43, a PEG ratio of 2.30 and a beta of 1.32. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. Option Care Health, Inc. has a 1 year low of $21.64 and a 1 year high of $34.63. The firm’s fifty day simple moving average is $28.82 and its 200 day simple moving average is $29.44.

Hedge Funds Weigh In On Option Care Health

Large investors have recently made changes to their positions in the business. Barclays PLC grew its holdings in Option Care Health by 180.1% in the 3rd quarter. Barclays PLC now owns 310,194 shares of the company’s stock valued at $9,708,000 after buying an additional 199,454 shares during the last quarter. Pier Capital LLC increased its position in Option Care Health by 88.4% during the third quarter. Pier Capital LLC now owns 231,884 shares of the company’s stock worth $7,258,000 after acquiring an additional 108,783 shares during the period. Orion Portfolio Solutions LLC raised its stake in Option Care Health by 2.3% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,232 shares of the company’s stock valued at $884,000 after purchasing an additional 636 shares during the last quarter. Zacks Investment Management boosted its holdings in Option Care Health by 7.4% in the 3rd quarter. Zacks Investment Management now owns 60,578 shares of the company’s stock valued at $1,896,000 after purchasing an additional 4,168 shares during the period. Finally, iSAM Funds UK Ltd acquired a new stake in Option Care Health in the 3rd quarter worth $371,000. Institutional investors and hedge funds own 98.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on OPCH. The Goldman Sachs Group cut Option Care Health from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $38.00 to $27.00 in a research report on Monday, November 4th. Jefferies Financial Group cut Option Care Health from a “buy” rating to a “hold” rating and lowered their price target for the company from $38.00 to $26.00 in a research note on Thursday, October 31st. Bank of America lowered shares of Option Care Health from a “buy” rating to a “neutral” rating and cut their price objective for the company from $43.00 to $29.00 in a research report on Wednesday, October 30th. JMP Securities boosted their target price on shares of Option Care Health from $36.00 to $37.00 and gave the stock a “market outperform” rating in a research report on Monday, September 30th. Finally, Barrington Research cut their price target on shares of Option Care Health from $40.00 to $32.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.83.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.